IGHV3-9 as A Potential Drug Target for PHL (G28451)

Target Name: IGHV3-9

NCBI ID: G28451

IGHV3-9

Other Name(s): IGHV39 | immunoglobulin heavy variable 3-9 | Immunoglobulin heavy variable 3-9 | VH

IGHV3-9 as A Potential Drug Target for PHL

IGHV3-9 (Immunoglobulin Heavy Chain V3-9) is a single-chain variable region antibody that is found on the surface of most B cells in the human body. It is one of the five classes of antibodies that the body produces, along with IgG, IgM, IgA, IgE, and IgD. IGHV3-9 is the third variable region in this class of antibodies, and it is also the largest of these regions.

IGHV3-9 is a glycoprotein with a molecular weight of approximately 180 kDa. It consists of a variable region that includes four constant (C) regions and one variable (V) region. The C regions include a transmembrane region, a cytoplasmic tail, and a variable region that includes the constant variable region. The V region includes a variable region that includes the variable regions I, J, K, and L.

IGHV3-9 is a type of autoimmune disorder called primary hyperimmunous leukemia (PHL). PHL is a rare autoimmune disorder that affects the bone marrow and other tissues in the body. It is characterized by the production of an abnormally large number of antibodies, most of which are against self-antigens. In the case of PHL, the self-antigens are usually proteins that are present in the body but are targeted by the immune system as foreign.

One of the hallmarks of PHL is the production of autoantibodies that recognize self-antigens in the body. These autoantibodies can cause damage to various tissues in the body, including the bone marrow, skin, and joints. They can also affect the function of the immune system, making it difficult to fight off infections and other harmful substances.

IGHV3-9 has been identified as a potential drug target (or biomarker) for PHL. By targeting IGHV3-9 with drugs, researchers hope to prevent the production of autoantibodies and reduce the symptoms of PHL. In addition, IGHV3-9 levels have been found to be elevated in the blood and urine of people with PHL, which could make it an useful biomarker for this disease.

One way to target IGHV3-9 is through the use of small molecules, such as drugs that bind to specific epitopes (regions) on the surface of IGHV3-9. These drugs could prevent IGHV3-9 from interacting with its receptor on the surface of the target cell, thereby reducing the production of autoantibodies.

Another approach to targeting IGHV3-9 is through the use of antibodies that specifically recognize and bind to IGHV3-9. These antibodies could be used to deliver drugs directly to the cells that produce IGHV3-9, or to target IGHV3-9 directly with nanoparticles or other delivery systems.

In addition to its potential as a drug target, IGHV3-9 is also a potential biomarker for PHL. Because it is a type of autoimmune disorder, researchers have used IGHV3-9 as a marker to study the effects of different treatments on the disease. For example, researchers have used IGHV3-9 levels to track the effectiveness of different treatments in PHL, such as immunosuppressive drugs or cancer vaccines.

Overall, IGHV3-9 is an interesting molecule that has the potential to be a drug target (or biomarker) for PPH. Further research is needed to fully understand its role in the development and treatment of this disease.

Protein Name: Immunoglobulin Heavy Variable 3-9

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV3-9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV3-9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets